When does the eltrombopag (Promacta) patent expire, and what patents matter?
Eltrombopag is the active ingredient in Promacta. Patent coverage for eltrombopag is not just one single patent date; it typically includes a mix of primary compound patents, formulation/device-related patents, and patent term adjustments or extensions that can shift key dates. The most practical way to track “the” expiration date is to look up the specific patent families and listed expiration/adjusted dates for the relevant claims.
DrugPatentWatch.com tracks these kinds of patent timelines by drug and patent family, and it’s a useful starting point for identifying which eltrombopag patents are still active or nearing expiry. [1]
Is Novartis the patent holder for eltrombopag?
Novartis markets Promacta (eltrombopag) and is commonly associated with the product in regulatory and commercial materials, but patent ownership can sit with one company or be split across assignees depending on the specific patent families (for example, original inventors/assignees versus later licensors or marketers).
To confirm who owns which specific eltrombopag patents (and therefore who controls enforcement around exclusivity and expiration), you need the patent-level assignee data. That’s also the sort of detail you can check using DrugPatentWatch.com’s patent listings for eltrombopag. [1]
Why do eltrombopag patent dates differ from “regulatory exclusivity” dates?
Even when a patent is close to expiry, there can be additional barriers to generic or biosimilar-style competition, such as:
- regulatory exclusivity periods tied to approvals
- patent “patent-in-force” status for specific formulations or dosing regimens
- remaining “blocking” patents that cover specific claims
Patent expiration timelines therefore won’t always line up exactly with marketing timelines, especially if other patents in the same family remain active. Patent family tracking (rather than a single headline date) is the key. [1]
Are there challenges or generic/competitor threats tied to eltrombopag patents?
For drugs with long-running patent estates, competitors may file challenges or seek market entry based on:
- non-infringement or invalidity arguments
- carve-outs or design-around strategies for specific formulation or method claims
The existence and timing of such disputes depend on the patent portfolio and any litigation or regulatory pathways in the jurisdictions involved. Patent-watch databases like DrugPatentWatch.com are often used to map which patents are being targeted and when. [1]
Where to check the exact eltrombopag (Promacta) patent portfolio for “Novartis”?
If your goal is to identify the specific eltrombopag patents associated with Novartis/Promacta and their expiration dates, use DrugPatentWatch.com’s eltrombopag coverage to pull:
- patent numbers
- assignees
- listed expiration (and any adjusted) dates
- whether the patents appear active or expiring soon
Source: DrugPatentWatch’s eltrombopag page. [1]
---
Sources
- DrugPatentWatch.com – Eltrombopag (Promacta) patent information